Hepatitis B virus (HBV) replicates essentially exclusively in the liver by reverse transcription of the 3.5-kb pregenomic RNA, generating the partially double-stranded 3.2-kb HBV DNA genome (12, 28, 45) . Viral tropism is probably determined in part by a liver-specific receptor that is required for HBV infection of hepatocytes. However, viral replication is also restricted to hepatocytes due to the essential requirement for the liver-enriched transcription factors hepatocyte nuclear factor 4 (HNF4) and the retinoid X receptor ␣ (RXR␣) plus the peroxisome proliferator-activated receptor ␣ (PPAR␣) heterodimer (RXR␣-PPAR␣) that regulate the synthesis of the pregenomic RNA (44) . The level of synthesis of the pregenomic RNA is governed by the activity of the nucleocapsid promoter (15, 44) . A variety of ubiquitous and liver-enriched transcription factors in addition to the nuclear hormone receptors HNF4 and RXR␣-PPAR␣, appear to modulate the rate of transcription initiation from the nucleocapsid promoter (4, 17, 20, 22, 25, 26, 35, 43, 46, 48) . However, it has been demonstrated that nuclear hormone receptor-dependent viral replication can be inhibited by the liver-enriched transcription factor HNF3 due to the preferential inhibition of pregenomic RNA synthesis relative to precore RNA synthesis (44) . The mechanism of regulation of 3.5-kb HBV RNA synthesis and inhibition of viral replication by HNF3 have not been defined and are examined in the current analysis.
In this study, the functional domain of HNF3␤ responsible for regulating nuclear hormone receptor-dependent 3.5-kb HBV RNA synthesis and viral replication has been investigated in mouse fibroblasts. HNF3␤ is a member of the hepatocyte nuclear factor 3/forkhead transcription factor family (19, 21, 23) . The members of this family of transcription factors are characterized by a conserved winged helix DNA binding domain that is approximately 100 amino acids in length (8, 19, 21) . The HNF3 polypeptides have additional conserved sequences in the amino-and carboxyl-terminal regions, flanking the DNA binding domain that is located in the middle of the polypeptide (19) . In the case of HNF3␤, these conserved amino acid sequences have been shown to comprise part of the transcriptional activation domains of this polypeptide (32, 33) . In this analysis, the amino-terminal transcriptional activation domain of HNF3␤ (32, 33) was shown to be primarily responsible for inhibiting viral replication, whereas the carboxyl-terminal transcriptional activation domain of HNF3␤ (32, 33) did not greatly affect HBV DNA synthesis. The inhibitory effect of this HNF3␤ domain on viral replication contrasts with the observation that the amino-terminal transcriptional activation domain was responsible for the increase in reporter gene expression mediated by the HBV large surface antigen and nucleocapsid promoters. These results suggested that the lower level of the 3.5-kb HBV RNA might be due to HNF3␤ reducing the rate of 3.5-kb HBV RNA elongation rather than negatively regulating nucleocapsid promoter activity. This possibility was supported by the observation that HNF3␤ could reduce viral replication when pregenomic RNA was synthesized from the cytomegalovirus (CMV) immediate-early promoter rather than the HBV nucleocapsid promoter. In addition, the ability of HNF3␤ to preferentially decrease the level of the pregenomic RNA compared with precore RNA produced conditions where hepatitis B e antigen (HBeAg) also contributed to the reduction in viral biosynthesis. Therefore, it appears that HNF3␤ inhibits HBV replication by reducing pregenomic RNA abundance by transcriptional interference and modulating the effect of HBeAg on viral biosynthesis.
MATERIALS AND METHODS
Plasmid constructions. The steps in the cloning of the plasmid constructs used in the transfection experiments were performed by standard techniques (38) . HBV DNA sequences in these constructions were derived from the pCP10 plasmid, which contains two copies of the HBV genome (subtype ayw) cloned into the EcoRI site of pBR322 (10) . The firefly luciferase (LUC) reporter gene in these constructions was derived from the p19DLUC plasmid (36) . The CpLUC plasmid contains one complete HBV genome located directly 5Ј to the promoterless LUC reporter gene such that the expression of the LUC gene is governed by the HBV nucleocapsid promoter (36) . Similarly, the PS1pLUC plasmid contains one complete HBV genome located directly 5Ј to the promoterless LUC reporter gene such that the expression of the LUC gene is governed by the HBV large surface antigen promoter (36) . Details of the construction of the CpLUC and PS1pLUC plasmids have been described previously (36, 47) .
The HBV DNA (4.1-kbp) construct that contains 1.3 copies of the HBV genome includes the viral sequence from nucleotide coordinates 1072 to 3182 plus 1 to 1990 (Fig. 1A) . This plasmid was constructed by cloning the NsiI/BglII HBV DNA fragment (nucleotide coordinates 1072 to 1990) into pUC13, generating pHBV(1072-1990). Subsequently, a complete copy of the 3.2-kbp viral genome linearized at the NcoI site (nucleotide coordinates 1375 to 3182 plus 1 to 1374) was cloned into the unique NcoI site (HBV nucleotide coordinate 1374) of pHBV(1072-1990), generating the HBV DNA (4.1-kbp) construct. The pCMVHBVayw construct contains the CMV immediate-early promoter (region from nucleotide coordinates Ϫ522 to Ϫ1) (3) located directly upstream of the HBV sequence from nucleotide coordinates 1821 to 3182 plus 1 to 1990 (Fig.  1B) . In this construct, the expression of the HBV pregenomic 3.5-kb RNA is controlled by the CMV immediate-early promoter.
The HBV DNA (4.1-kbp) E1mut and E2mut constructs were derived by introducing the A1816G and G1898A nucleotide substitutions (Fig. 1C) , respectively, into the precore coding region in the HBV DNA (4.1-kbp) construct using the Chameleon double-stranded, site-directed mutagenesis kit (Stratagene Cloning Systems, La Jolla, Calif.) according to the manufacturer's instructions. The A1816G nucleotide substitution converted the precore initiation codon from ATG to GTG, preventing the initiation of translation of the precore polypeptide. The G1898A nucleotide substitution converted the precore polypeptide TGG codon 28 encoding tryptophan to the amber translation termination TAG codon, resulting in the premature termination of the precore polypeptide (1, 18, 31) . The nucleotide substitutions introduced into the precore coding regions were verified by dideoxynucleotide sequencing (39) . Both precore coding regions in these terminally redundant HBV constructs were mutated for this analysis.
The pMTHNF1␣, pMTHNF1␤, pCMVHNF3␣, pCMVHNF3␤, pCMVHNF4, pRS-hRXR␣, and pCMVPPAR␣-G vectors express HNF1␣, HNF1␤, HNF3␣, HNF3␤, HNF4, RXR␣, and PPAR␣-G polypeptides from the rat HNF1␣, mouse HNF1␤, rat HNF3␣, rat HNF3␤, rat HNF4, human RXR␣, and mouse PPAR␣-G cDNAs, respectively, using the mouse metallothionein I promoter, the CMV immediate-early promoter (pCMV), or the Rous sarcoma virus long terminal repeat (pRS) (6, 27, 30, 34, 35, 37) . The PPAR␣-G polypeptide contains a mutation in the PPAR␣ cDNA changing Glu 282 to Gly that may decrease the affinity of the receptor for the endogenous ligand. Consequently, this mutation increases the peroxisome proliferator-dependent (i.e., clofibric acid-dependent) activation of transcription from a peroxisome proliferator response element (PPRE) containing promoter (30) and was used in this study to demonstrate the peroxisome proliferator-dependent transcriptional transactivation of the nucleocapsid promoter.
Cells and transfections. The mouse NIH 3T3 fibroblast cell line was grown in RPMI 1640 medium and 10% fetal bovine serum at 37°C in 5% CO 2 and air. Transfections using luciferase reporter gene constructs were performed as previously described (14, 41) , except six-well plates, containing approximately 3 ϫ 10 5 cells per well, were used. The transfected DNA mixture comprised 5 g of a LUC plasmid and 0.25 g of pCMV␤, which served as an internal control for transfection efficiency. pCMV␤ directs the expression of the Escherichia coli ␤-galactosidase gene using the CMV immediate-early promoter (Clontech Laboratories, Palo Alto, Calif.). When appropriate, the DNA mixture also included 0.5 g of the HNF3␤ expression vectors pCMVHNF3␤, pCMVHNF3␤1-444, pCMVHNF3␤1-392, pCMVHNF3␤1-366, pCMVHNF3␤1-309, pCM-VHNF3␤103-458, pCMVHNF3␤153-458, and pCMVHNF3␤144-279 or the control expression vector pCMV. The numbers at the end of the plasmid designation indicate the amino acid residues present in the truncated HNF3␤ polypeptides encoded by these expression vectors (32, 33) . The DNA was removed 4 to 6 h after transfection, and the cells were washed with 2 ml of fresh RPMI 1640 medium. Cell extracts were prepared 40 to 48 h after transfection. Cells were lysed in 150 l of lysis buffer [0.1 M potassium phosphate (pH 7.8), 0.2% (vol/vol) Triton X-100], and the cell debris was pelleted by centrifugation for 2 min at 13,000 rpm in an Eppendorf 5417C microcentrifuge. The supernatant was assayed for luciferase activity essentially as previously described (9) and for ␤-galactosidase activity using a Galacto-Light kit (Tropix, Inc.) as instructed by the manufacturer. The level of ␤-galactosidase activity observed was not specifically affected by any of the exogenously expressed transcription factors. The luciferase activities were normalized to the level of ␤-galactosidase activity in each transfection experiment.
Transfections for viral RNA and DNA analyses were performed as previously described (29) using 10-cm-diameter plates, containing approximately 10 6 cells. DNA and RNA isolation was performed 3 days posttransfection. The transfected DNA mixture was composed of 10 g of HBV DNA (4.1 kbp) plus 1.5 g of the liver-enriched transcription factor expression vectors pMTHNF1␣, pMTHNF1␤, pCMVHNF3␣, pCMVHNF3␤, pCMVHNF4, pRS-hRXR␣, and pCMVP-PAR␣-G (6, 27, 30, 34, 35, 37, 44) . Controls were derived from cells transfected with HBV DNA and the pCMV expression vector lacking a liver-enriched transcription factor cDNA insert (35) . All-trans retinoic acid and clofibric acid at 1 M and 1 mM, respectively, were used to activate the nuclear hormone receptors RXR␣ and PPAR␣ (44) .
Characterization of HBV transcripts and viral replication intermediates. Transfected cells from a single plate were divided equally and used for the preparation of total cellular RNA and viral DNA replication intermediates as described previously (42) with minor modifications. For RNA isolation (7), the cells were lysed in 1.8 ml of a solution containing 25 mM sodium citrate (pH 7.0), 4 M guanidinium isothiocyanate, 0.5% (vol/vol) sarcosyl, and 0.1 M 2-mercaptoethanol. After addition of 0.18 ml of 2 M sodium acetate (pH 4.0), the lysate was extracted with 1.8 ml of water-saturated phenol plus 0.36 ml of chloroformisoamyl alcohol (49:1). After centrifugation for 30 min at 3,000 rpm in a Sorval RT6000 centrifuge, the aqueous layer was precipitated with 1.8 ml of isopropanol. The precipitate was resuspended in a solution containing 0.3 ml of 25 mM sodium citrate (pH 7.0), 4 M guanidinium isothiocyanate, 0.5% (vol/vol) sarcosyl, and 0.1 M 2-mercaptoethanol and precipitated with 0.6 ml of ethanol. After centrifugation for 20 min at 14,000 rpm in an Eppendorf 5417C microcentifuge, the precipitate was resuspended in 0.3 ml of a solution containing 10 mM Tris hydrochloride (pH 8.0), 5 mM EDTA, and 0.1% (wt/vol) sodium lauryl sulfate and precipitated with 45 l of 2 M sodium acetate plus 0.7 ml of ethanol.
For the isolation of viral DNA replication intermediates, the cells were lysed in 0.4 ml of 100 mM Tris hydrochloride (pH 8.0) plus 0.2% (vol/vol) Nonidet P-40. The lysate was centrifuged for 1 min at 14,000 rpm in an Eppendorf 5417C microcentrifuge to pellet the nuclei. The supernatant was adjusted to 6.75 mM magnesium acetate plus 200 g of DNase I per ml and incubated for 1 h at 37°C to remove the transfected plasmid DNA. The supernatant was readjusted to 100 mM NaCl, 10 mM EDTA, 0.8% (wt/vol) sodium lauryl sulfate, and 1.6 mg of pronase per ml and incubated for an additional 1 h at 37°C. The supernatant was extracted twice with phenol, precipitated with 2 volumes of ethanol and resuspended in 100 l of 10 mM Tris hydrochloride (pH 8.0) plus 1 mM EDTA. RNA (Northern) and DNA (Southern) filter hybridization analyses were performed using 10 g of total cellular RNA and 30 l of viral DNA replication intermediates, respectively, as described previously (38) .
RNase protection assays were performed using the Pharmingen Riboquant kit, and riboprobes were synthesized using the Ambion Maxiscript kit as described by the manufacturers. Transcription initiation sites for the 3.5-kb HBV transcripts were examined using 20 g of total cellular RNA and a 333-nucleotide-long (HBV coordinates 1990 to 1658) 32 P-labeled HBV riboprobe. As an internal control for the RNase protection analysis, a 32 P-labeled mouse ribosomal protein L32 gene riboprobe spanning 101 nucleotides of exon 3 was utilized (11) . All riboprobes contained additional flanking vector sequences of 40 to 90 nucleotides that are not protected by HBV RNA.
Whole-cell extracts and gel retardation analysis. Whole-cell extracts were prepared from mouse NIH 3T3 fibroblasts by a rapid micropreparation technique as described previously (2) . Mouse fibroblasts were transfected with 15 g of the expression vectors encoding the truncated HNF3␤ polypeptides 40 to 48 h before preparation of the whole-cell extracts. Gel retardation analysis was performed essentially as described previously (34, 37) . One nanogram of 32 P-labeled CpE double-stranded oligonucleotide was incubated with 4 l of whole-cell extract prior to 4% polyacrylamide gel electrophoresis and autoradiography. The CpE double-stranded oligonucleotides spanning a HNF3 site in the nucleocapsid promoter have been described previously (20) . 
RESULTS
Expression of truncated HNF3␤ polypeptides in mouse fibroblasts. HNF3 has previously been shown to activate transcription from the HBV nucleocapsid promoter in reporter gene analysis (37) and to inhibit pregenomic RNA synthesis and viral biosynthesis in HBV replication analysis (44) . In an attempt to examine these apparently contradictory observations, the functional domains of HNF3␤ modulating HBV transcription and replication were examined. If the same domain of HNF3 were found to activate transcription from the HBV nucleocapsid promoter in reporter gene analysis and to inhibit pregenomic RNA synthesis and viral biosynthesis in HBV replication analysis, the same mechanism may be involved in both processes. In contrast, if different domains of HNF3 were found to be involved in these processes, different mechanisms may also be involved. Initially, various truncated HNF3␤ polypeptides lacking either the amino-or carboxylterminal transcriptional activation domains (32, 33) were expressed in mouse NIH 3T3 fibroblasts ( Fig. 2A) . Electrophoretic mobility shift analysis demonstrated that the truncated HNF3␤ polypeptides were expressed at similar levels and retained the ability to bind to a HNF3 recognition sequence present in the HBV nucleocapsid promoter (Fig.  2B) . The truncated HNF3␤ polypeptide spanning amino acids 1 to 309 (Fig. 2B, lane 6 ) displayed the lowest level of DNA binding activity but was completely functional with respect to modulating HBV transcription and replication ( Fig. 3 and 4) . Therefore, it appears that any differences in the level of expression of the truncated HNF3␤ polypeptides used in this analysis did not influence greatly the function of these transcription factors.
Identification of the HNF3␤ polypeptide domains involved in regulating HBV transcription and replication in mouse fibroblasts. The domain of the HNF3␤ polypeptide involved in inhibiting HNF4-mediated HBV transcription and replication was examined in mouse NIH 3T3 fibroblasts (Fig. 3A to C) . It is apparent that the carboxyl-terminal domain of the HNF3␤ polypeptide was not required for the inhibition of viral transcription and replication. In contrast, inhibition of viral transcription and replication was reduced when the amino-terminal domain of the HNF3␤ polypeptide was deleted (Fig. 3A to C, lanes 9). This indicates that the amino-terminal transcriptional activation domain located in the first 153 amino acids of HNF3␤ was necessary to inhibit HBV transcription and replication. The truncated HNF3␤ polypeptide spanning amino acids 103 to 458 (Fig. 3A to C, lanes 8 ) appeared to partially inhibit HBV RNA and DNA syntheses. This observation suggested that the functional domain of HNF3␤ modulating HBV transcription and replication may include polypeptide sequences located between amino acid residues 1 and 102 in addition to amino acid residues between coordinates 103 and 152. The DNA binding domain of HNF3␤ located between amino acid residues 144 and 279 was unable to inhibit HNF4-mediated HBV transcription and replication (Fig. 3A to C) despite retaining the ability to bind to a HNF3 recognition element (Fig. 2B) . This is consistent with the mapping of the HNF3␤ domain inhibiting HBV transcription and replication within the amino-terminal region of this transcription factor. In addition, it is apparent that the full-length and carboxylterminus-truncated HNF3␤ polypeptides inhibited viral replication to a greater extent than HBV transcription. These observations suggested that these HNF3␤ polypeptides might decrease the level of synthesis of the pregenomic RNA to a greater extent than that of the precore RNA (44) .
Despite the ability of HNF3␤ to inhibit HNF4-mediated HBV transcription and replication, HNF3␤ can activate transcription from the nucleocapsid promoter in the context of a reporter gene construct in mouse NIH 3T3 fibroblasts (Fig.  3D) . Therefore, the domain of the HNF3␤ polypeptide responsible for activating transcription in this context was examined using the HBV nucleocapsid and large surface antigen promoter constructs CpLUC and PS1pLUC, respectively. HNF3␤ activates transcription from these promoters approximately 10-and 75-fold, respectively. It is apparent that the carboxyl-terminal domain of the HNF3␤ polypeptide was not required for the activation of transcription from the nucleocapsid or large surface antigen promoters. In contrast, the truncated polypeptides lacking the amino-terminal transcriptional activation domain located in the first 153 amino acids of HNF3␤ displayed a greatly reduced ability to increase the level of transcription from either the nucleocapsid or large surface antigen promoter (Fig. 3D) . As observed for the inhibition of HBV transcription and replication, deletion of the first 102 amino acids of HNF3␤ resulted in a partial loss of transcriptional activation (Fig. 3D , compare HNF3␤ and HNF3␤103-458). Transcriptional activation was reduced further from the HBV promoters when the complete amino-terminal domain was deleted from the HNF3␤ polypeptide (Fig. 3D , compare HNF3␤ and HNF3␤153-458). Therefore, it is apparent that the amino-terminal transcriptional activation domain of HNF3␤ mediated the majority of both the activation of transcription from the nucleocapsid and large surface antigen promoters using the reporter gene constructs and the inhibition of viral transcription and replication from the HBV DNA (4.1-kbp) construct in mouse fibroblasts. In addition, it appears that the extent to which the amino-terminal deletions activated transcription correlates with the degree to which HBV transcription and replication are inhibited. The observation that HNF3␤ activates transcription from HBV reporter gene constructs under the same conditions where HBV RNA and DNA synthesis are inhibited eliminates the possibility that HNF3␤ inhibits viral transcription and replication by the process of squelching (13) . The amino-terminal transcriptional activation domain of HNF3␤ was also predominantly responsible for the inhibition of RXR␣-PPAR␣-mediated HBV transcription and replication in mouse fibroblasts (Fig. 4) . This indicates that HNF3␤ can inhibit HBV transcription and replication that is dependent on more than a single nuclear hormone receptor and suggests that HNF3␤ may indirectly influence HBV pregenomic RNA synthesis in the context of viral replication. As observed with HNF4, the amino-terminal region between residues 1 and 102 partially inhibited HBV transcription and replication ( Fig. 4A and B, lanes 8) . However, deletion of the complete amino-terminal domain of HNF3␤ (Fig. 4A and B, lanes 9) essentially eliminated the capacity of this polypeptide to modulate HBV RNA and DNA syntheses. These observations support the suggestion that amino acid sequences within the first 102 residues and between residues 103 to 152 contribute to the functional domain of HNF3␤ responsible for the inhibition of HBV transcription and replication.
Role of HBeAg in the inhibition of HBV replication by HNF3␤ in mouse fibroblasts. It was previously observed that HNF3 inhibition of nuclear hormone receptor-mediated HBV replication in mouse NIH 3T3 fibroblasts was associated with a greater decrease in the pregenomic RNA than in the precore RNA (44) . This results in a modest increase in the precore RNA/pregenomic RNA ratio (Fig. 5) . The effect of the truncated HNF3␤ polypeptides on the relative abundance of the precore and pregenomic RNAs was examined (Fig. 5) . It appears that the truncated HNF3␤ polypeptides lacking the carboxyl-terminal transcriptional activation domain also inhibited the synthesis of the pregenomic RNA to a greater extent than that of the precore RNA (Fig. 5 , lanes 4 to 7 and 13 to 16) although possibly to a lesser extent than the full-length HNF3␤ polypeptide (Fig. 5, lanes 3 and 12) . In contrast, the relative abundance of the precore and pregenomic RNAs observed in the absence of HNF3␤ (Fig. 5, lanes 2 and 11) was similar to that observed in mouse fibroblasts transfected with the trun- 18 and 19) . Therefore, it appears that HNF3␤ polypeptides that efficiently inhibit HBV replication also preferentially decrease the level of pregenomic RNA relative to the precore RNA (Fig. 5B) . Under these circumstances, it appears that the reduction in the level of viral replication is somewhat greater than the reduction in pregenomic RNA synthesis (Fig. 3 to 5 ). This indirect evidence tentatively suggested that the translation product of the precore RNA, the HBeAg polypeptide, might contribute to the inhibition of viral replication. This possibility is supported by previous observations suggesting that HBeAg can inhibit HBV replication (5, 16, 40) . The possibility that HBeAg expression might contribute to the inhibition of viral replication by HNF3␤ in mouse fibroblasts was investigated directly (Fig. 6) . Two replication-competent viral constructs, HBV DNA (4.1-kbp) E1mut and E2mut, were examined to determine if HNF3␤ can inhibit viral replication in the absence of HBeAg synthesis. It was observed that HBeAg synthesis does not appear to inhibit HNF4-mediated (Fig. 6A, lanes 2, 7, and 12 ) or RXR␣-PPAR␣-mediated viral replication (Fig. 6A, lanes 4, 9, and 14) . However, it is apparent that HNF3␤ inhibits HNF4-and RXR␣-PPAR␣-mediated wild-type viral replication approximately 8-and 16-fold, respectively (Fig. 6A, lanes 2 to 5) . In contrast, HNF3␤ inhibits HNF4-and RXR␣-PPAR␣-mediated viral replication approximately three-and fourfold, respectively, from the HBV DNA (4.1-kbp) E1mut construct that cannot express HBeAg (Fig. 6A, lanes 7 to 10) . HNF3␤ also inhibits HNF4-and RXR␣-PPAR␣-mediated viral replication approximately three-and fourfold, respectively, from the HBV DNA (4.1-kbp) E2mut construct that also cannot express HBeAg (Fig.  6A, lanes 12 to 15) . In contrast to the different effects of HNF3␤ on viral replication, HNF3␤ reduced 3.5-kb RNA synthesis from the wild-type and HBeAg-minus viral genomes to similar extents (Fig. 6) . Therefore, it is appears that HNF3␤ inhibits viral replication from the wild-type viral genome partly by an HBeAg-dependent mechanism. This presumably occurs because HNF3␤ decreases the level of the HBeAg-encoding precore RNA less than the core polypeptide-encoding pregenomic RNA. Consequently, it appears that HBeAg can inhibit viral replication efficiently only when the pregenomic RNA level is low relative to the precore RNA, as HBeAg does not appear to affect viral replication in the absence of HNF3␤ (Fig. 6A, lanes 2, 4, 7, 9, 12, and 14) . However, HNF3␤ can inhibit viral replication from constructs that cannot express HBeAg. This indicates that HNF3␤ also inhibits viral replication by directly reducing the level of pregenomic RNA in addition to altering the relative level of HBeAg expression (Fig. 6) .
HNF3␤ inhibits HBV pregenomic RNA synthesis from a heterologous promoter in mouse fibroblasts. Nuclear hormone receptor-mediated HBV pregenomic RNA synthesis regulated by the nucleocapsid promoter is inhibited by HNF3␤ in mouse NIH 3T3 fibroblasts ( Fig. 5 and 6 ). In contrast, HNF3␤ activates transcription from the nucleocapsid promoter when the transcript encodes the luciferase gene (Fig. 3D ). This suggests that HBV regulatory elements present within the transcribed region of the HBV DNA (4.1-kbp) construct might be involved in inhibiting the synthesis of the pregenomic RNA. The observations that HNF3 recognition sequences are present in all the HBV promoters and transcription of the pregenomic RNA requires that RNA synthesis transverses these regulatory regions suggest HNF3␤ might inhibit pregenomic RNA synthesis by interfering with pregenomic RNA elongation. If this were the case, the nature of the promoter directing the expression of the pregenomic RNA should not influence the ability of HNF3␤ to inhibit pregenomic RNA synthesis and HBV replication. The pCMVHBVayw construct directs the expression of the pregenomic RNA from the CMV immediate-early promoter. Viral replication occurs from the pregenomic RNA synthesized from this construct in the absence of nuclear hormone receptors in mouse fibroblasts ( Fig. 7A and B, lanes 1) . The ectopic expression of HNF1␣, HNF1␤, HNF4, and RXR␣-PPAR␣ does not inhibit viral transcription or replication (Fig. 7, lanes 2, 3, 6 , and 7). HNF4 and RXR␣-PPAR␣ appear to modestly enhance viral transcription and replication from the pCMVHBVayw construct. In contrast, HNF3␣ and HNF3␤ inhibit viral transcription and replication approximately fourfold. HNF3 does not directly affect the activity of the CMV immediate-early promoter (H. Tang and A. McLachlan, unpublished data). These observations suggest that HNF3 may inhibit pregenomic RNA synthesis from a regulatory sequence element, probably a HNF3 recognition sequence, located downstream from the transcription initiation site of the pregenomic RNA. This appears to represent a new level of transcriptional regulation that may ensure that transcription from the HBV promoters is coordinately regulated so that appropriate levels of viral products are synthesized to support efficient viral biosynthesis.
DISCUSSION
HBV replication is restricted to hepatocytes partly because pregenomic RNA synthesis is regulated by liver-enriched transcription factors (44) . Transcriptional regulation of HBV by the nuclear hormone receptors HNF4 and RXR␣ plus PPAR␣ is a critical determinant in restricting viral replication to the liver (44) . However, additional liver-enriched transcription factors can modulate nuclear hormone receptor-mediated HBV transcription and replication in mouse fibroblasts. HNF3 negatively regulates viral transcription and replication in this system (44) . This observation was unexpected, as HNF3 has been demonstrated to activate transcription from the nucleocapsid promoter in reporter gene analysis (20, 24, 37) . Therefore, it appeared that in the context of viral replication, HNF3 was affecting viral 3.5-kb RNA transcription from HBV regulatory elements located within the transcribed region of pregenomic RNA.
The mechanism of action of HNF3␤ on HBV transcription and replication was investigated in mouse fibroblasts using both viral replication and reporter gene analyses. In both cases, it was shown that the amino-terminal transcriptional activation domain of HNF3␤ (32, 33) was responsible for inhibiting HBV replication in the viral replication analysis and for activating transcription from the nucleocapsid promoter in the reporter gene analysis (Fig. 3 and 4) . These results suggested the inhibition of viral replication is mediated by the activation of transcription from one or more of the HBV promoters.
Previously, it had been suggested that HNF3␤ preferentially inhibited the transcription of the pregenomic RNA compared with that of precore RNA (44) . This observation was confirmed and shown to be dependent on the presence of the amino-terminal transcriptional activation domain in the HNF3␤ polypeptide (Fig. 5) . This suggested that HNF3␤ influences the selection of the transcription initiation site from the nucleocapsid promoter, and consequently, the level of the HBeAg-encoding precore RNA is reduced less than the core polypeptide-encoding pregenomic RNA. The fact that the decrease in viral replication due to HNF3␤ expression is larger than expected for the reduction in pregenomic RNA suggested that the higher relative level of HBeAg synthesis compared with that of the core polypeptide might contribute to the HNF3␤-mediate inhibition of viral replication. HBeAg has been shown to inhibit HBV replication in a variety of systems (5, 16, 40) . This possibility was investigated by examining the ability of HNF3␤ to inhibit viral replication from mutated HBV genomic DNA templates that were not capable of expressing HBeAg (Fig. 6 ). Under these circumstances, HNF3␤ inhibited HBV replication but to a considerably lesser extent than from a template that encoded the HBeAg polypeptide. This analysis indicated that HBeAg contributes to the inhibition of viral replication in mouse fibroblasts under certain circumstances. HNF3␤ mediates the inhibition of viral replication partly by decreasing the level of precore RNA less than that of the pregenomic RNA and consequently decreasing the level of HBeAg less than that of the core polypeptide. If the HBeAg polypeptide can inhibit replication-competent capsid assembly from occurring as has been suggested (40), a greater decrease in core polypeptide synthesis than that in HBeAg synthesis could result in a larger than expected decrease in viral biosynthesis. However, alterations in the relative levels of the precore and pregenomic RNAs can account for only part of the HNF3␤-mediated inhibition of nuclear hormone receptormediated viral replication. It is apparent that HNF3␤ directly inhibits the level of the pregenomic RNA. This effect is not dependent of the nature of the promoter that is directing the expression of the pregenomic RNA (Fig. 7) . When the CMV immediate-early promoter is used to direct the expression of the HBV pregenomic RNA, HNF3␣ and HNF3␤ reduced both the levels of this transcript and viral replication. This demonstrated that HNF3 inhibits HBV transcription and replication from regulatory elements located within the pregenomic RNA transcription unit. As the amino-terminal transcriptional activation domain is required to inhibit pregenomic RNA synthesis and viral replication, these observations suggest that HNF3␤ inhibits pregenomic RNA synthesis by promoting transcription from a downstream HBV promoter such as the large surface antigen, major surface antigen, or the X-gene promoters. As the 2.1-kb HBV RNA level is reduced by HNF3␤ expression (Fig. 3, 4, 6 and 7) , it is unlikely that the reduction in 3.5-kb HBV RNA synthesis results from HNF3-mediated transcription from the major surface antigen promoter. However, it suggests that the formation of a transcriptionally active preinitiation complex containing HNF3 at one of the other HBV promoters downstream from the nucleocapsid promoter may restrict the efficiency of elongation of the pregenomic RNA through this region of the viral genome. This would reduce the level of the pregenomic RNA and inhibit viral replication. This is regulation of viral replication by transcriptional interference and represents an additional novel level of regulation of HBV replication.
Although less direct, the possibility that HNF3 might activate the transcription of cellular gene(s) that may selectively increase the rate of turnover of the HBV transcripts cannot be excluded. This possibility would also result in a reduction in pregenomic RNA abundance and the inhibition of viral replication. Additional studies will be required to define the detailed steps mediated by HNF3 that control the steady-state level of the HBV pregenomic RNA. A role for the X-gene product in the inhibition of viral replication by HNF3 can be excluded, as viral genomes that do not encode this polypeptide are susceptible to HNF3-mediated inhibition of HBV DNA synthesis (Tang and McLachlan, unpublished) .
